Treatment of non-small cell lung cancer in the older patient

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 2, 2012, Pages 230-239

  Ganti, Apar Kishor ^a,b   DeShazo, Mollie ^c   Weir III, Alva B ^d,e   Hurria, Arti ^f  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Comprehensive geriatric assessment; Non small cell lung cancer; Older individuals

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINBLASTINE;

ADJUVANT THERAPY; ALOPECIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CARDIOTOXICITY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MENTAL DISEASE; META ANALYSIS; METASTASIS; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SENESCENCE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84856833532     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0021     Document Type: Review

References (62)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Avery EJ, Kessinger A, Ganti AK. Therapeutic options for elderly patients with advanced non-small cell lung cancer. Cancer Treat Rev 2009;35:340-344.
3. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067. (Pubitemid 30035956)
4. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-1389. (Pubitemid 46606420)
5. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 2001;19:1064-1070. (Pubitemid 32176282)
6. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239-1246. (Pubitemid 30321574)
7. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983;31:721-727. (Pubitemid 14209563)
8. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
9. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005;23:6865-6872.
10. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-1831. (Pubitemid 46860271)
11. Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011;29:1290-1296.
12. Biesma B, Wymenga AN, Vincent A, et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol 2011;22:1520-1527.
13. Audisio RA, Pope D, Ramesh HS, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008;65:156-163.
14. Audisio RA, Ramesh H, Longo WE, et al. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist 2005;10:262-268. (Pubitemid 40559591)
15. Pope D, Ramesh H, Gennari R, et al. Pre-operative assessment of cancer in the elderly (PACE): a comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery. Surg Oncol 2006;15:189-197. (Pubitemid 46771201)
16. Ramsdale EE, Polite BN, Bylow KA, et al. Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 9000.
17. Soubeyran P, Bellera C, Goyard J, et al. Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 9001.
18. Cudennec T, Gendry T, Labrune S, et al. Use of a simplified geriatric evaluation in thoracic oncology. Lung Cancer 2010;67:232-236.
19. Extermann M, Boler I, Reich R, et al. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: design and validation [abstract]. J Clin Oncol 2010;28(Suppl):Abstract 9000.
20. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457-3465.
21. Mizushima Y, Noto H, Sugiyama S, et al. Survival and prognosis after pneumonectomy for lung cancer in the elderly. Ann Thorac Surg 1997;64:193-198. (Pubitemid 27313904)
22. Ettinger DS, Akerley W, Borghaei H, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2, 2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf. Accessed January 3, 2012.
23. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
24. Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 2007;25:1553-1561. (Pubitemid 46733082)
25. Wisnivesky JP, Smith CB, Packer S, et al. Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study. BMJ 2011;343:d4013.
26. Movsas B, Scott C, Sause W, et al. The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 1999;45:1143-1149.
27. Werner-Wasik M, Scott C, Cox JD, et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000;48:1475-1482.
28. Langer CJ, Hsu C, Curran WJ, et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10 [abstract]. J Clin Oncol 2002;21(Suppl):Abstract 1193.
29. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003;21:3201-3206. (Pubitemid 46606250)
30. Rocha Lima CM, Herndon JE II, Kosty M, et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002;94:181-187. (Pubitemid 34049057)
31. Schild SE, Mandrekar SJ, Jatoi A, et al. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 2007;110:363-368. (Pubitemid 47121897)
32. Beretta GD, Michetti G, Belometti MO, et al. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 2000;83:573-576. (Pubitemid 30636295)
33. Comella P, Frasci G, Carnicelli P, et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004;91:489-497. (Pubitemid 39093568)
34. Hesketh PJ, Chansky K, Lau DH, et al. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 2006;1:537-544. (Pubitemid 47181401)
35. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181. (Pubitemid 34162751)
36. Langer C, Li S, Schiller J, et al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007;25:418-423. (Pubitemid 350002990)
37. Sweeney CJ, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001;92:2639-2647. (Pubitemid 33049448)
38. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353. (Pubitemid 41095099)
39. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001;6(Suppl 1):4-7. (Pubitemid 32155180)
40. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663. (Pubitemid 46630541)
41. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer 2001;34(Suppl 4):S65-69.
42. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372. (Pubitemid 36395256)
43. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-1088.
44. Abe T, Yokoyama A, Takeda K, et al. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): an intergroup trial of JCOG0803/WJOG4307L [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 7509.
45. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529-2536. (Pubitemid 30432518)
46. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003;94:15-21. (Pubitemid 36575852)
47. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009;373:1033-1040.
48. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
49. Gonsalves W, Ganti AK. Targeted anti-cancer therapy in the elderly. Crit Rev Oncol Hematol 2011;78:227-242.
50. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
51. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:2350-2357.
52. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550. (Pubitemid 44917502)
53. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
54. Cangemi V, Volpino P, D'Andrea N, et al. Lung cancer surgery in elderly patients. Tumori 1996;82:237-241. (Pubitemid 26253715)
55. Naunheim KS, Kesler KA, D'Orazio SA, et al. Lung cancer surgery in the octogenarian. Eur J Cardiothorac Surg 1994;8:453-456.
56. Jack CI, Lye M, Lesley F, et al. Surgery for lung cancer: age alone is not a contraindication. Int J Clin Pract 1997;51:423-426. (Pubitemid 27477593)
57. Morandi U, Stefani A, Golinelli M, et al. Results of surgical resection in patients over the age of 70 years with non small-cell lung cancer. Eur J Cardiothorac Surg 1997;11:432-439. (Pubitemid 27146150)
58. Ishida T, Yokoyama H, Kaneko S, et al. Long-term results of operation for non-small cell lung cancer in the elderly. Ann Thorac Surg 1990;50:919-922.
59. Langer C, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10 [abstract]. Proc Am Soc Clin Oncol 2002;21:Abstract 299a.
60. Kelly K, Giaritta S, Akerley W, et al. Should older patients (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308 [abstract]. J Clin Oncol 2001;20(Suppl):Abstract 1313.
61. Langer C, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70) [abstract]. J Clin Oncol 2003;22(Suppl):Abstract 2571.
62. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-196. (Pubitemid 41702638)